Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00600886 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 358
- Enrollment target
NCT00600886 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 358 participants.
The verdict
NCT00600886, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 358 participants
- Enrollment target
Study Summary
The patients received either Pasireotide LAR or Octreotide LAR for one year of treatment. The objective of this study was to compare the proportion of patients with a reduction of mean GH level to \<2.5 µg/L and the normalization of IGF-1 to within normal limits (age and sex related) between the two treatment groups (pasireotide LAR and octreotide LAR) at 12 months. Following one year of treatment patients could proceed into the study extension. Patients who did not respond to the treatment they were randomized to (based on month 12 assessment results) were switched to the other treatment arm at month 13.
Interventions
- DRUG Pasireotide
- DRUG Octreotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 358 participants |
| Start Date | 2008-02-11 |
| Est. Completion | 2016-03-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00600886
The ClinicalTrials.gov registry entry for NCT00600886 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 358 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pasireotide is the first listed.
NCT00600886 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00600886 about?
NCT00600886 is a clinical study titled "Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly". The patients received either Pasireotide LAR or Octreotide LAR for one year of treatment. The objective of this study was to compare the proportion of patients with a reduction of mean GH level to \<2.5 µg/L and the normalization of IGF-1 to within normal limits (age and sex related) between the tw...
What is the current status of trial NCT00600886?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 358 participants. The study started on 2008-02-11. Estimated completion is 2016-03-11.
What interventions are being tested in trial NCT00600886?
The interventions under investigation include: Pasireotide (DRUG), Octreotide (DRUG).
Who is sponsoring clinical trial NCT00600886?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.